Coherus Oncology inc (CHRS) - News Archive

In the ever-evolving landscape of cancer immunotherapy, the latest data unveiled by Coherus Oncology at the Society for Immunotherapy of Cancer (SITC) conference highlights a promising leap forward in precision medicine...

Coherus Biosciences, a biopharmaceutical company focused on the development of innovative immunotherapies, has recently made significant strides in the field of oncology. During the upcoming American Society of Clinical...

Coherus s Innovative Antibodies Show Potential in the Treatment of Cancer: A Closer Look at CHS-114, LOQTORZI, and CasdozokitugThe field of oncology is constantly evolving, with new therapeutic options emerging to comba...

Coherus Biosciences Inc, a leading biotechnology and pharmaceutical company, recently announced significant financial developments and updates in a press release. The company disclosed a new $38.7 million term loan with...

Coherus BioSciences, Inc. has recently announced a new clinical collaboration with the Cancer Research Institute (CRI) for evaluating a novel combination therapy for the treatment of ovarian cancer. The collaboration wi...

Coherus Presents Promising Data for CHS-1000, a Novel Anti-ILT4 Antibody, at 2024 AACR Annual MeetingCoherus BioSciences, a leading biotechnology company, recently presented encouraging preclinical data for their ground...

Coherus Biosciences, a leading biopharmaceutical company, has recently completed the divestiture of its Ophthalmology Franchise, resulting in an upfront cash payment of $170 million. This strategic move aims to strength...

Coherus BioSciences Announces New Employment Inducement GrantsOn February 20, 2024, Coherus BioSciences, Inc. (Nasdaq: CHRS) granted options to purchase an aggregate of 170,000 shares of common stock to three newly hire...

In recent news, Coherus Biosciences Inc, a leading biopharmaceutical company, has announced significant developments regarding its financial standing and debt obligations. Despite recording a cumulative net loss of $-21...

Coherus Focuses on Oncology with Strategic TransactionCoherus Biosciences Inc has recently announced a strategic transaction that aligns with the company s focus on oncology. The move comes after the company recorded a...

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers SymposiumIn a recent press release, Coherus Biosciences announced that its investiga...

Coherus BioSciences, Inc. Grants Options to New Employees, Impacting ShareholdersREDWOOD CITY, Calif., Dec. 22, 2023 - Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) announced today that it has granted...

Coherus Announces Revolutionary Breakthrough: LOQTORZI Positioned as the Ultimate First-Line Treatment for Nasopharyngeal CancerIn a groundbreaking revelation, Coherus Biosciences Inc. unveiled the updated position of L...

Coherus Biosciences Inc., a leading biotechnology company, presented significant findings at the 2023 ESMO Immuno-Oncology Congress regarding the potential of their novel IL-27-targeted antibody, Casdozokitug. In combin...